VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TLXTelix Pharmaceuticals Limited
$10.00$3.4B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTLXPrice Target
TLX logo

Telix Pharmaceuticals Limited (TLX) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 5 analysts

88.3% Below Target

TLX trades 88.3% below Wall Street's consensus target of $19.00.

Current Price$10.00
Average Target$19.00
Target
Current
Low$17.00
Median$20.00
High$20.00

Analyst Target Range

Forward P/E171.0x
(High Premium)
PEG Ratio—
Implied Growth-69.8%
(Declining)
Analyst Spread15.8%
(High Agreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$10.00
Consensus$19.00
High$20.00
Low$17.00

Consensus Scenario Assumptions

The base valuation assumes TLX achieves its forward estimates and maintains a stable P/E multiple of 171.0x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 5 published analyst recommendations for TLX

4/5 analysts are bullish
+40
BearishBullish
Weighted analyst sentiment score based on 5 ratings
ConsensusBuy
Coverage5 Analysts
Net Score+40
Bull / Bear80% / 0%
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
480%
Hold
120%
Sell
00%
Strong Sell
00%
Recommendation Mix80% Buy · 20% Hold · 0% Sell
Buy (4)Hold (1)Sell (0)

TLX Price Target Analysis

Updated June 23, 2026

As of June 23, 2026, Telix Pharmaceuticals Limited (TLX) has a Wall Street consensus price target of $19.00, based on estimates from 5 covering analysts. With the stock currently trading at $10.00, this represents a potential upside of +88.3%. The company has a market capitalization of $3.39B.

Analyst price targets range from a low of $17.00 to a high of $20.00, representing a 16% spread in expectations. The median target of $20.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.

The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, TLX trades at a trailing P/E of -455.3x and forward P/E of 171.0x. Analysts expect EPS to grow -69.8% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $20.49, with bear and bull scenarios of $12.91 and $27.00 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+34.3%
Industry Consensus
Avg Forward P/E
16.0x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
EXEL logo
EXELExelixis, Inc.
$13.0B$51.35$47.33
-8.8%
Buy14.7x32
RNW logo
RNWReNew Energy Global Plc
$2.3B$6.43$6.39
+1.1%
Buy0.5x6
AGEN logo
AGENAgenus Inc.
$127M$3.04$7.33
+144.3%
Buy3.8x11
LNTH logo
LNTHLantheus Holdings, Inc.
$6.9B$106.13$108.50
+4.5%
Buy19.4x17
NVS logo
NVSNovartis AG
$284.2B$148.93$170.00
+15.6%
Hold16.9x25
BMY logo
BMYBristol-Myers Squibb Company
$111.7B$54.70$62.60
+15.9%
Hold8.5x41
PRAX logo
PRAXPraxis Precision Medicines, Inc.
$8.8B$303.00$584.00
+106.9%
Buy—16
GE logo
GEGE Aerospace
$371.0B$355.12$380.14
+6.3%
Buy47.4x34
GEHC logo
GEHCGE HealthCare Technologies Inc.
$27.6B$60.64$81.10
+31.7%
Buy12.6x18
SYK logo
SYKStryker Corporation
$116.8B$304.64$387.46
+25.9%
Buy20.5x51

TLX — Frequently Asked Questions

Quick answers to the most common questions about buying TLX stock.

What is the TLX stock price target for 2026?

The consensus Wall Street price target for TLX is $19, representing 88.3% upside from the current price of $10. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is TLX a buy, sell, or hold?

TLX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies 88.3% upside from current levels.

Is TLX stock overvalued or undervalued?

At a forward P/E of 171.0169x, TLX trades at a premium valuation. The consensus price target of $19 (88.3% upside) suggests analysts still see growth justifying the multiple.

How high can TLX stock go?

The most bullish Wall Street analyst has a price target of $20 for TLX, while the most conservative target is $17. The consensus of $19 represents the median expectation. Our quantitative valuation model projects a bull case target of $27 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover TLX stock?

TLX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the TLX stock forecast?

The 12-month TLX stock forecast based on 5 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $17 (bear case) to $20 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $20, with bear/bull scenarios of $13/$27.

What is TLX's fair value based on fundamentals?

Our quantitative valuation model calculates TLX's fair value at $20 (base case), with a bear case of $13 and bull case of $27. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.

What is TLX's forward P/E ratio?

TLX trades at a forward P/E ratio of 171.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy TLX stock?

Wall Street analysts are very optimistic on TLX, with a "Buy" consensus rating and $19 price target (88.3% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do TLX price targets vary so much?

TLX analyst price targets range from $17 to $20, a 16% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground. Our model's $13-$27 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare